SHR-2524
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Hepatocellular Carcinoma: Phase 1. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SHR-2524: this drug | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Cabozantinib | Approved | Small molecule | MET / VEGFR / AXL / RET (multi-kinase) | Partial signal | NCT01908426: Overall Survival (OS) (Up to 45 months): Cabozantinib (XL184) 10.2 months (95% CI 9.1 to 12) | Placebo 8 months (95% CI 6.8 to 9.4) | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ipilimumab | Approved | Monoclonal antibody | CTLA-4 antagonist | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary in this indication | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | NCT03062358: Overall Survival (OS) (Up to approximately 4 years): Pembrolizumab + BSC 14.6 Months (95% CI 12.6 to 18) | Placebo + BSC 13 Months (95% CI 10.5 to 15.1) | |
| Ramucirumab | Approved | Monoclonal antibody | VEGFR2 | Partial signal | NCT02435433: Overall Survival (OS) (From Date of Randomization to Death from Any Cause (Up to 28 Months)): Ramucirumab + Best Supportive Care (BSC) 8.51 Months (95% CI 7 to 10.58) | Placebo + BSC 7.29 Months (95% CI 5.42 to 9.07) | |
| Regorafenib | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | not yet graded | No reviewed efficacy summary in this indication | |
| Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs) | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Tremelimumab | Approved | Monoclonal antibody | CTLA-4 | Partial signal | No reviewed efficacy summary in this indication | |
| Amezalpat | Phase 3 | Small molecule | PPARα (peroxisome proliferator-activated receptor alpha) | not yet graded | No reviewed efficacy summary in this indication | |
| Apatinib | Phase 3 | Small molecule | VEGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| BGB-B2033 | Phase 3 | Multispecific antibody | GPC3 (glypican-3) x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| Cadonilimab | Phase 3 | Multispecific antibody | PD-1×CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Camrelizumab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| JS207 | Phase 3 | Multispecific antibody | PD-1 + VEGFA | not yet graded | No reviewed efficacy summary in this indication | |
| Namodenoson | Phase 3 | — | Adenosine A3 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Nilvanstomig | Phase 3 | Biologic (subtype unspecified) | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| Pegargiminase | Phase 3 | Protein / enzyme therapeutic | Arginine-depleting pegylated arginine deiminase | not yet graded | No reviewed efficacy summary in this indication | |
| Penpulimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Rilvegostomig | Phase 3 | Multispecific antibody | PD-1 and TIGIT | not yet graded | No reviewed efficacy summary in this indication | |
| RYZ801 | Phase 1/2 | Radiopharmaceutical | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-324 | Phase 1 | Antibody–drug conjugate | Glypican-3 (GPC3) / Topoisomerase I | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| SENTI-301A | Phase 1 | Cell therapy | GPC3 (CAR-NK, calibrated IL-15) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD7003 | —(overall) | Cell therapy | Glypican-3 (GPC3) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SHR-2524 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.